# An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer

Source: https://onco.cc/trials/nct00532194/  
OnCo record `nct00532194` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Cediranib in Ovarian cancer, run by Medical Research Council, with a status the registry has not verified recently.

## Summary

An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer is a phase 3 interventional study registered as NCT00532194 by Medical Research Council, with 486 participants planned, started 2007-07 and due to reach its primary completion in 2013-04. Interventions recorded: cediranib. Conditions recorded: Ovarian Cancer.

Linked to the drug Cediranib because the registry names it among its interventions and Ovarian cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00532194
- Phase: 3
- Setting: A Randomised, Placebo-controlled, Trial of Concurrent Cediranib [AZD2171] (With Platinum-based Chemotherapy) and Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer
- Sponsor: Medical Research Council
- Enrolled: 486

## Sources

- ClinicalTrials.gov NCT00532194: https://clinicaltrials.gov/study/NCT00532194

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Cediranib](https://onco.cc/drugs/cediranib/)

---
JSON: https://onco.cc/api/v1/entities/nct00532194.json